Abstract
Objective: Demographic and laboratory values predicting clinical severity in Covid-19 patients have been a matter of curiosity since the beginning of the disease. We aimed to show the relationship between the severity of Covid-19 disease and comorbidities, clinical and laboratory features of the patients.
Material and Methods: The data of Covid-19 patients diagnosed with polymerase chain reaction (PCR), were analyzed retrospectively. The patients were divided into 3 groups according to their clinical severity as mild, moderate and severe. Comorbidities and the Charlson Comorbidity Index (CCI) at the time of diagnosis were calculated for each patient from the patients' records. Demographic data, laboratory values, comorbidity and CCI scores were compared between the patient groups. The effect of CCI on survival and length of hospital stay was examined.
Results: One hundred and four patients were included in the trial. The most common comorbid disease in the patients included in the trial was hypertension. The moderate-severe stage patients were statistically significantly older (p<0,001). The CCI was found to be statistically significantly different between mild, moderate and severe groups (p<0,001). When CCI increases by one unit, the risk of death increases by 1.193 times (p=0.017). Older age, WBC, neutrophil count, BUN, creatinine, AST, potassium level, CRP, procalcitonin, aPTT, fibrinogen, d-dimer, and ferritin levels were found to be higher in the clinically severe patient group. Lymphocyte and eosinophil counts, total protein, albumin and sodium levels were found to be lower in the clinically severe patient group.
Conclusion: This trial showed that calculating the CCI score in Covid-19 patients can be useful in predicting the severity of the disease. Examination of CCI, age, WBC, neutrophil, lymphocyte, eosinophil counts, BUN, creatinine, AST, total protein, albumin, sodium, potassium level, CRP, procalcitonin, aPTT, fibrinogen, d-dimer and ferritin levels at the time of diagnosis can be suggested.
References
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
- Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 759-65.
- Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020; 7: 671-8.
- Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol 2020; 92: 1915-21.
- Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020; 14: 303-10.
- Matsushita K, Ding N, Kou M, et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Glob Heart 2020; 15: 64.
- Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One 2020; 15: e0238215.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83.
- Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39: 405-7.
- Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130: 2620-9.
- Christensen DM, Strange JE, Gislason G, et al. Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients. J Gen Intern Med 2020; 35: 2801-3.
- Sun Y, Dong Y, Wang L, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun 2020; 112: 102473.
- Wendel Garcia PD, Fumeaux T, Guerci P, et al. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine 2020; 25: 100449.
- Bastug A, Bodur H, Erdogan S, et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. Int Immunopharmacol 2020; 88: 106950.
Abstract
References
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
- Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 759-65.
- Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020; 7: 671-8.
- Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol 2020; 92: 1915-21.
- Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020; 14: 303-10.
- Matsushita K, Ding N, Kou M, et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Glob Heart 2020; 15: 64.
- Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One 2020; 15: e0238215.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83.
- Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39: 405-7.
- Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130: 2620-9.
- Christensen DM, Strange JE, Gislason G, et al. Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients. J Gen Intern Med 2020; 35: 2801-3.
- Sun Y, Dong Y, Wang L, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun 2020; 112: 102473.
- Wendel Garcia PD, Fumeaux T, Guerci P, et al. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine 2020; 25: 100449.
- Bastug A, Bodur H, Erdogan S, et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. Int Immunopharmacol 2020; 88: 106950.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Original Article |
| Authors | |
| Publication Date | March 28, 2021 |
| Published in Issue | Year 2021 Volume: 4 Issue: 2 |
Cited By
The relationship between thoracic CT findings and C-reactive protein and ferritin levels in COVID-19 patients
Journal of Health Sciences and Medicine
https://doi.org/10.32322/jhsm.1258459
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.